Abstract:This bioequivalence study was conducted to evaluate two oral formulations of cotrimoxazole tablets in healthy Chinese subjects. All 26 subjects recruited to this study were randomly and evenly classified into two groups and received a single dose (sulfamethoxazole: 400 mg and trimethoprim: 80 mg) of test cotrimoxazole tablets (generic drug) or reference cotrimoxazole tablets (branded drug). After a 7-day washout period, these subjects received one dose of reference drug or test drug. Blood samples were collected from participants before and up to 48 h after dosing to assess the concentration of sulfamethoxazole (SMX) and trimethoprim (TMP) in plasma and a plasma concentration-time curve was drawn. Then, the pharmacokinetics parameters were calculated accordingly. Our data revealed that there were no significant differences observed in the maximum plasma concentration (Cmax), area under the curve from time 0 to the last measurable concentration (AUC0-t), and area under the curve from time 0 to infinity (AUC0-∞) between the two formulations. For SMX, the 90% confidence intervals (CI) of the geometric mean ratio for Cmax, AUC0-t, and AUC0-∞ were 104.03-113.92%, 100.46-103.70%, and 100.41-103.81%, respectively. Similarly, for Trimethoprim (TMP), the 90% CI ranged from 98.54 to 106.95% for Cmax, from 99.31 to 107.68% for AUC0-t, and from 99.49 to 107.55% for AUC0-∞. Importantly, all these 90% CI values fell within the range of 80.00–125.00%, indicating that the test drug is bioequivalent to the reference drug. Furthermore, throughout the entire trial, no suspected serious adverse events were reported, indicating the safety profile of the newly developed generic cotrimoxazole. In summary, our study demonstrates that the newly developed generic formulation of cotrimoxazole is bioequivalent to the branded formulation under fasting conditions.

[Pharmacokinetics and Bioequivalence of Trimebutine Dispersive Tablet in Healthy Subjects].

Study on bioequivalence of trimetazidine capsule and tablet in healthy volunteers

Bioequivalence and pharmacokinetic study of trimetazidine dihydrochloride in human plasma by using LC-MS/MS

Bioequivalence of trimetazidine dihydrochloride tablets in Chinese healthy subjects

Pharmacokinetics and Bioequivalence of Rebamipide Dispersible Tablets in Healthy Volunteers

Determination of Huperzine A in Human Plasma by LC-MS/MS and Its Application to Relative Bioavailability of Huperzine A Tablets

LC/ESI-MS Method for the Determination of Trimetazidine in Human Plasma: Application to a Bioequivalence Study on Chinese Volunteers.

Pharmacokinetics and Bioequivalance of Clarithromycin Dispersed Tablet in Healthy Volunteers

Evaluation of Bioequivalence of Mirtazapine Tablets

Bioequivalence of Clarithromycin Dispersed Tablet in Health Volunteers

Pharmacokinetics and Bioequivalence of Eperisone Hydrochloride Tablet in Healthy Subjects

Pharmacokinetics and Bioequivalence of Anethol Trithione in Chinese Healthy Volunteers

Pharmacokinetics and bioequivalence evaluation of two oral formulations of cotrimoxazole tablets in healthy Chinese volunteers under fasting conditions

Determination of Gliquidone in Human Plasma by LC-MS/MS and Bioequivalence Study of Its Two Tablets

Study on the Bioequivalence of Rabeprazole Enteric- Coated Tablets in Human Plasma

[Pharmacokinetics and Bioequivalence of Domestic Trimetazidine Formulations].

Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers.

Bioequivalence of Risperidone Orally Disintegrating Tablets in Healthy Volunteers

Pharmacokinetics and Bioequivalence of Finasteride Tablets in Healthy Subjects

HPLC-MS method to investigate the bioequivalence of diltiatem extended action tablets

Bioequivalence and Pharmacokinetic Profiles of 2 Trimetazidine Modified-release Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects